Health Care · Pharmaceutical Preparations

ABT Abbott Laboratories SEC Filings & Insider Trading Activity 2026

company
CIK 1800110 filings
S&P 500

ABT at a glance

Abbott Laboratories (ABT, SEC CIK 1800) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Abbott Laboratories (ABT) reported revenue of $44.3 billion (up 5.7% from FY2024) and net income of $6.5 billion. Diluted EPS was $3.72.
  • As of September 30, 2026, 71 institutional investment managers tracked by SignalX reported holding Abbott Laboratories (ABT) shares worth $63.3 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Moreland Mary K on November 5, 2026 of 3,500 shares at $116.00 per share.
  • In the last 90 days, ABT insiders reported 0 open-market purchases ($0) and 6 open-market sales ($92.8M) on Form 4, a net sale of $92.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$44.3B
+5.7% vs prior year
Insiders · 90 days
0 buys · 6 sells
Net −$92.8M
13F holders
71 funds
$63.3B · −4 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 5.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • IRS tax disputes over 2017-2020 SNODs totaling $1.05B contested, involving income reallocation between U.S. and foreign affiliates
  • Malaysian tax authorities assessed $413M capital gains tax on 2023 intercompany share sale; Penang High Court upheld, Abbott appealed in 2025
  • Supply chain tariffs and foreign exchange fluctuations increased costs, partially offsetting margin improvement which led to only a 52.6% gross margin in 2025
  • Competitive pressure from biosimilars and off-patent medicines expansion in emerging markets challenges Established Pharmaceuticals segment growth
  • Debt maturity exposure with $3.0B of $12.9B total debt due in 2026, plus $20B unsecured bridge loan commitment related to Exact Sciences acquisition

Management Discussion & Analysis

  • Revenue $44.2B in 2025, up 5.7% YoY excluding foreign exchange impact
  • Operating margin 18.2% in 2025 vs 16.3% in 2024; Medical Devices margin 33.7% vs 32.4%
  • Best segment: Medical Devices sales up 12.6% (to approx. $19.9B); worst: Diagnostics sales down 4.3% with margin decline to 19.5% from 24.4%
  • Cash and short-term investments $8.9B; long-term debt $12.9B; dividends $4.1B, increased 7.1% to $2.40/share in 2025
  • 2026 outlook: focus on growth in diagnostics (Alinity platform), medical devices, nutrition product innovation and emerging market pharmaceutical expansion

Business Overview

  • Core business model centered on healthcare products and medical technologies, with no new product lines detailed in 2026 filing
  • Notable new segment emphasis: merger agreement dated November 19, 2025 with Exact Sciences Corporation
  • Strategic shift: Amended and restated By-Laws effective December 12, 2025, indicating governance updates
  • Quantitative metric: Allowances for doubtful accounts and product returns increased to $490M in 2025 from $439M in 2024
  • Most noteworthy fact: Inclusion of significant merger-related documents and ongoing update of compensation and governance policies in 2026 Proxy Statement

AI summary of the ABT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $13.0B, up 14.5% YoY, with foreign exchange reducing growth by 0.3%
  • Gross margin 50.3% vs 51.7% YoY, pressured by Exact Sciences amortization, higher costs, and foreign exchange
  • Best segment Diagnostic Products, $3.3B, up 46.7%; worst Nutritional Products, $2.3B, up 5.1%
  • Cash $4.1B vs $8.5B at December 31; operating cash flow $5.5B, down approximately $700M YoY
  • Exact Sciences acquisition funded with $20.0B debt; $1.0B share repurchases and $0.63 quarterly dividend per share

AI summary of the ABT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Change-in-control agreements extended through December 31, 2028 for named executives other than CEO Robert B. Ford
  • Ford’s change-in-control agreement expires December 31, 2026
Filed Oct 21, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 operating results announced October 21, 2026, with detailed figures in Exhibit 99.1
  • Abbott highlighted adjusted net earnings excluding acquisition, legal, restructuring, regulatory and tax-related items

Item EX-99.1: Item EX-99.1

  • Q3 sales $13.013B, up 14.5% reported and 7.0% comparable, led by Diagnostics comparable growth of 6.4%
  • Adjusted diluted EPS $1.42, up 9.2%, while GAAP EPS fell to $0.53 after $1.557B of specified charges
Filed Oct 21, 2026Full analysis →

Item 8.01: Other Events

  • Planned separation of global nutrition business into an independent, publicly traded company
  • Potential portfolio simplification, allowing Abbott to focus on remaining healthcare businesses

Item EX-99.1: Item EX-99.1

  • Planned tax-free spin-off gives Abbott shareholders shares in both companies, subject to approvals and Form 10 effectiveness
  • Nutrition business targets independence by end-2027, with approximately $8.5B sales, 16,000 employees and 14 manufacturing sites

AI summaries of ABT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ABT

Don't miss the next ABT filing

  • Alerts as it files. A push when ABT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ABT, by share count.
  • Ask anything. An AI agent that reads every ABT filing and answers with sources.

ABT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Moreland Mary KSellNov 5, 2026$116.00
Gonzalez Patricia PaolaASep 30, 2026$98.83
Ahuja NitaASep 30, 2026$98.83
Conroy Kevin TASep 30, 2026$98.83
Stratton John GASep 30, 2026$98.83
Roman Michael FASep 30, 2026$98.83
Conroy Kevin TFSep 23, 2026$103.99
MCCOY JOHN A. JR.SellSep 2, 2026$109.54

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$42.0B$44.3B
Operating Income-$6.8B$8.1B
Net Income$5.7B$13.4B$6.5B
Op. Margin-16.3%18.2%
Net Margin-31.9%14.7%
Balance Sheet
Total Assets$73.2B$81.4B$86.7B
Equity-$47.7B$52.1B
ROE-28.1%12.5%
Per Share
EPS$3.26$7.64$3.72
Cash Flow
Operating CF-$8.6B$9.6B
CapEx$2.2B$2.2B$2.2B

Source: XBRL data in Abbott Laboratories (ABT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ABT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ABT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202671$63.26B
Q2 202675$59.13B
Q1 202677$66.71B
Q4 202573$80.73B
Q3 202575$92.33B
Q2 202572$89.58B
Q1 202571$65.84B
Q4 202468$43.56B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 582 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ABT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 16, 2026Analysis-
4Nov 6, 2026--
10-QNov 4, 2026Analysis
8-KOct 21, 2026Analysis-
8-KOct 21, 2026Analysis-
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Sep 25, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Aug 27, 2026--
8-KAug 20, 2026Analysis-
4Aug 13, 2026--
10-QJul 28, 2026Analysis
8-KJul 16, 2026Analysis-
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jun 29, 2026--

Related Health Care companies

All Health Care →

ABT SEC filings: frequently asked questions

Are ABT insiders buying or selling?

In the last 90 days, Abbott Laboratories (ABT) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $92.8 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ABT stock?

As of September 30, 2026, the largest Abbott Laboratories (ABT) holders among the 13F filers tracked by SignalX were BlackRock ($15.0 billion), Vanguard Capital Management LLC ($11.2 billion), State Street Corp ($8.0 billion), Vanguard Portfolio Management LLC ($4.7 billion), JPMorgan Chase & Co ($3.0 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ABT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Abbott Laboratories (ABT) reported revenue of $44.3 billion (up 5.7% from FY2024) and net income of $6.5 billion. Diluted EPS was $3.72. The figures come from the XBRL data in the 10-K.

What are the main risks in ABT's latest 10-K?

In the 10-K filed February 20, 2026, Abbott Laboratories (ABT) flagged: IRS tax disputes over 2017-2020 SNODs totaling $1.05B contested, involving income reallocation between U.S. and foreign affiliates. Malaysian tax authorities assessed $413M capital gains tax on 2023 intercompany share sale; Penang High Court upheld, Abbott appealed in 2025. (AI summary of the Risk Factors section.)

What did ABT report in its latest 8-K?

Abbott Laboratories (ABT) filed an 8-K on November 16, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Change-in-control agreements extended through December 31, 2028 for named executives other than CEO Robert B. Ford.

What are the latest ABT SEC filings?

Abbott Laboratories (ABT) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 6, 2026.

What is ABT's SEC CIK number?

Abbott Laboratories (ABT)'s SEC Central Index Key (CIK) is 1800. EDGAR lists every ABT filing under that number.

Ask anything about ABT

The research agent reads ABT's filings, financials, insider trades and 13F holders, then answers with sources.